Papillomavirus Infections Clinical Trial
Official title:
Evaluation of Safety and Immunogenicity of GARDASIL™ in Healthy Females Between 9 and 26 Years of Age in SubSaharan Africa
The study is designed to determine the safety, tolerability and immunogenicity of a 3-dose regimen of GARDASIL™ administered to healthy females between 9 and 26 years of age, in Sub-Saharan Africa. Data from the current study are needed in order to complement existing extensive safety data from the GARDASIL™ clinical trials program, and confirm that GARDASIL™ may be administered safely and will induce immune responses in populations from and living in Sub-Saharan Africa, as GARDASIL™ has not previously been studied in this region of the world.
In Phase A of the study, healthy females between 9 and 12 years of age will be randomized (4:1) to receive the 3-dose regimen of GARDASIL™ or placebo, and those between 13 and 26 years old will receive GARDASIL™. In Phase B of the study, participants who received placebo in Phase A will have the option to receive the 3-dose regimen of GARDASIL™. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00973856 -
Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands
|
N/A | |
| Active, not recruiting |
NCT05580341 -
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
|
Phase 3 | |
| Completed |
NCT06399341 -
Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR).
|
||
| Recruiting |
NCT03548740 -
Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection
|
||
| Completed |
NCT00092547 -
A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)
|
Phase 3 | |
| Completed |
NCT00157950 -
Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)
|
Phase 3 | |
| Recruiting |
NCT00365729 -
Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) - Types in HIV-positive Men
|
N/A | |
| Completed |
NCT03584308 -
Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal
|
Phase 2 | |
| Not yet recruiting |
NCT04115787 -
Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN
|
||
| Completed |
NCT04072913 -
Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix
|
N/A | |
| Completed |
NCT00549250 -
Human Papillomavirus 6/11 in the Lower Airway of Neonates
|
N/A | |
| Recruiting |
NCT04694495 -
HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study
|
||
| Completed |
NCT06439433 -
ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection
|
Phase 2 | |
| Completed |
NCT00380367 -
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
|
Phase 3 | |
| Completed |
NCT01894425 -
Human Papillomavirus and Rate of Pregnancy Achieved Via Medically Assisted Procreation
|
N/A | |
| Completed |
NCT00685412 -
Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3
|
Phase 1 | |
| Completed |
NCT00365716 -
Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)
|
Phase 2 | |
| Completed |
NCT04772534 -
Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)
|
Phase 3 | |
| Completed |
NCT05119855 -
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
|
Phase 3 | |
| Completed |
NCT03487549 -
Cantharidin and Occlusion in Verruca Epithelium
|
Phase 2 |